Company intelligence

STOK

Stoke Therapeutics, Inc. · NASDAQ · Healthcare

Price$33.09-1.11% · −$0.37

Market cap2.14BEquity value

P / E-9.9Trailing ratio

Volume925.87KLatest session

Market data

STOK price chart

TradingView

Related signals

1 min delayed

Browse public STOK signals with their source context and measured market impact. Open any signal for its permanent analysis page.

STOKAug 3, 2026+7.14% since signal

Stoke targets 2027 rolling NDA for zorevunersen after EMPEROR readout

Stoke Therapeutics reports EMPEROR Phase 3 enrollment completed (162 patients) with readout anticipated in Q3 2027 and a pre-NDA meeting planned for H2 2026. The company also advances STK-002 for ADOA, with initial safety/efficacy data expected in H1 2027. With about $420 million in cash, Stoke aims for U.S. commercialization by early 2028, underpinning a multi-year regulatory path.

View signal analysis

STOKMar 18, 2025-5.28% since signal

Stoke Therapeutics Stock Slips as CEO Steps Down

Stoke CEO Dr. Edward Kaye resigns, interim CEO Ian Smith appointed. Q4 revenue reached $22.61 million, exceeding analyst consensus greatly. Company reported a smaller-than-expected loss of $0.18 per share. Stoke has $246.7 million in cash, funding operations through mid-2028. Shares fell nearly 3% but up over 40% in the last year.

View signal analysis

Research